Stocks · News reference
William Blair initiates Revvity (RVTY) at Outperform, citing AI tailwinds, life sciences recovery, and potential 20%+ stock upside.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Multiple financial institutions, including Stifel Nicolaus, Goldman Sachs, and JPMorgan, updated their price targets for Revvity on November 4, 2026, following the company's third-quarter earnings report.
Goldman Sachs increased its price target for Revvity, Inc. from $140 to $160.
Revvity (RVTY) reported Q3 2026 adjusted EPS of $1.38, beating estimates by 7%, with revenues rising 4.3% to $728.9M. Life Sciences revenues climbed 10.7% driven by strong pharma and biotech demand. The company raised its 2026 pro forma EPS guidance to $5.40-$5.45 and revenue forecast to $2.86B, reflecting 6% total growth and 5% organic growth.
Filed: 2026-11-03 AccNo: 0000031791-26-000031 Size: 871 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Revvity, Inc. reported third-quarter 2026 financial results, exceeding analyst expectations for both revenue and adjusted earnings per share.
Revvity, Inc. has declared a regular quarterly dividend of $0.07 per share of common stock.